Results 31 to 40 of about 9,938 (160)

Magnetic Micro‐ and Nanorobots for Precision Thrombolysis: Design Strategies and Translational Challenges

Advanced Robotics Research, EarlyView.
Micro‐ and nanorobots for targeted thrombolysis. This perspective elaborates on the clinical indication of blood clot disorders and current limitations for treatment. As a novel, alternative solution, micro‐ and nanorobots can be used to treat and break down thrombi.
Joshua M. Mesfin, Yimo Yan, Nikola Cesarovic, Simone Schuerle   +3 more
wiley   +1 more source

Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial

Trials, 2022
Background The effectiveness of alteplase for ischemic stroke treatment is limited, partly due to the occurrence of intracranial and extracranial hemorrhage. Mutant pro-urokinase (m-proUK) does not deplete fibrinogen and lyses fibrin only after induction
Nadinda A. M. van der Ende, Bob Roozenbeek, Lucas E. M. Smagge, Sven P. R. Luijten, Leo A. M. Aerden, Petra Kraayeveld, Ido R. van den Wijngaard, Geert J. Lycklama à Nijeholt, Heleen M. den Hertog, H. Zwenneke Flach, Alexis C. Wallace, Victor Gurewich, Gregory J. del Zoppo, William J. Meurer, Hester F. Lingsma, Aad van der Lugt, Diederik W. J. Dippel, on behalf of the DUMAS Investigators   +17 more
doaj   +1 more source

Age Is an Effect Modifier of Thrombectomy Benefit in a Socioeconomically Vulnerable Stroke Population

Annals of Neurology, EarlyView.
Objective Randomized trials from high‐income countries have shown that endovascular treatment (EVT) yields similar benefits in elderly and non‐elderly patients with large vessel occlusion stroke (LVOS). However, evidence from low/middle‐income countries remains scarce.
Fabricio O. Lima, Francisco José de A. Mont'Alverne, Letícia C. Rebello, Daniel G. Abud, Gisele S. Silva, Michel E. Frudit, Mário B. Wagner, Jamary Oliveira‐Filho, Diogo C. Haussen, David S. Liebeskind, Octávio M. Pontes‐Neto, Norberto A.F. Frota, Guilherme Dabus, Gabriel R. de Freitas, Adson F. de Lucena, Jeffrey L. Saver, Raul G. Nogueira, Sheila C.O. Martins, for the RESILIENT Trial Investigators   +18 more
wiley   +1 more source

Multivalent Bi‐Specific Nanoerythrosomes: A Two‐Birds‐One‐Stone Approach to Combine Homologous and Active Targeting for Effective Thrombolysis

Small, EarlyView.
A multivalent bi‐specific nanoerythrosome (mBiNE@tPA) is developed as a “two‐birds‐one‐stone” platform that simultaneously exploits two principal thrombus components. By integrating erythrocyte membrane‐mediated homologous targeting with cRGD‐based active targeting to activated platelets, mBiNE@tPA achieves enhanced thrombus accumulation, triggered ...
Yu Huang, Yilin Yang, Nicole Henry, Boram Gu, Jiahua Wang, Yuanyuan Guo, Colin Longstaff, Simon A. Thom, Yuehua Li, Xiao Yun Xu, Rongjun Chen   +10 more
wiley   +1 more source

Management of Kaposiform Haemangioendothelioma—A Retrospective Case Series Examining the Use and Effectiveness of Vincristine

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Aim Kaposiform haemangioendothelioma is a rare vascular tumour. Management has evolved over the last two decades, with most cases receiving vincristine or sirolimus. We aim to describe our experience with managing this tumour, with a focus on the safety and efficacy of vincristine.
Bronwen Kirk, Susan Adams, Orli Wargon, Artiene Tatian, Susan Russell   +4 more
wiley   +1 more source

Retrospective evaluation of two different thrombolytic agents in the treatment of patients with massive pulmonary embolism: Alteplase vs reteplase

Batı Karadeniz Tıp Dergisi
Aim: To compare clinical effectiveness of reteplase and alteplase in patients with massive pulmonary embolism.Material and Methods: Between 2010 and 2016 all patients treated with one of the thrombolytic agents, alteplase or reteplase, for massive ...
Hakan Tanrıverdi, Ayşegül Tomruk Erdem, Bülent Altınsoy, Müge Meltem Tor   +3 more
doaj   +1 more source

Abstract Number ‐ 259: Recanalization Before Completion of Alteplase Infusion Leads to Improved Outcomes: A Retrospective Analysis

Stroke: Vascular and Interventional Neurology, 2023
Introduction The recently published CHOICE trial found that intra‐arterial infusion of alteplase improved clinical outcomes in patients undergoing EVT for LVO AIS, an effect that was possibly due to a reduction in reperfusion‐related injury.
Ivo Bach, Alexandra L Czap, Deepa Dongarwar, Sunil A Sheth   +3 more
doaj   +1 more source

Hematoma Interleukin‐1 Receptor Antagonist Concentrations Predict Long‐Term Outcome in Acute Human Intracerebral Hemorrhage

Annals of Neurology, Volume 100, Issue 2, Page 345-360, August 2026.
Objectives The interleukin (IL)‐1, IL‐6, and C‐reactive protein (CRP) pathway is central to the immune response after intracerebral hemorrhage (ICH). We tested for associations between hematoma and plasma cytokine concentrations and patient outcomes in Minimally Invasive Surgery Plus Rt‐PA for ICH Evacuation Phase III (MISTIE III) participants ...
Adrian R. Parry‐Jones, Blessing Nyakutsikwa, Michael H. Askenase, Matthew Gittins, Mary Newland, Siobhan Crilly, Paul R. Kasher, Yvonne Davidson, Federico Roncaroli, Stuart M. Allan, Lauren H. Sansing, Wendy Ziai, Daniel F. Hanley, INFLAME‐ICH Investigators, Mark Harrigan, David Miller, Judy Huang, Wendy Ziai, Jack Jallo, Fred Rincon, Gaurav Gupta, Igor Rybinnik, Diederik Bulters, Mary Leigh Gelea, Andras Buki, Erzsebet Ezer, Hiren Patel, Adrian Parry‐Jones, Charles Matouk, Kevin Sheth / Lauren Sansing, Ali Zomorodi, Michael James, Pal Barzo, Krisztian Tanczos, Gregory Thompson, Ventatakrishna Rajajee/Aditya Pandey, Peter Nakaji, Shawn E. Wright, Walter Galicich, Thomas Bergman, Andrew Carlson, Huy Tran, Philipp Taussky, Safdar Ansari, Fuat Arikan, Marcelino Baguena, Ronald Reimer, W. David Freeman, Ania Pollack, John Terry, Geza Mezey, Katalin Szabo/Laszlo Csiba, Robert F. James, Steven J. Barrer, Larami MacKenzie   +54 more
wiley   +1 more source

A Systematic Review of the Efficacy and Safety of Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Time to Pass the Torch

Stroke: Vascular and Interventional Neurology
Alteplase, a biosynthetic form of human tissue‐type plasminogen activator, is Food and Drug Administration‐approved for the treatment of acute ischemic stroke and currently the standard of care for thrombolytic therapy.
Miguel Rodriguez, Christian Sidebottom, Drew A. Wells, Thirumalaivasan Dhasakeerthi, Lisa Hayes, Cheran Elangovan, Balaji Krishnaiah   +6 more
doaj   +1 more source

Low-dose vs. standard-dose intravenous alteplase for acute ischemic stroke with unknown time of onset

Frontiers in Neurology, 2023
BackgroundStandard-dose intravenous alteplase for acute ischemic stroke (AIS) in the unknown or extended time window beyond 4.5 h after symptom onset is both effective and safe for certain patients who were selected based on multimodal neuroimaging ...
Zekun Wang, Kangxiang Ji, Qi Fang
doaj   +1 more source